10/15/2009

MEDIMMUNE HIGHLIGHTS INFLAMMATORY DISEASE PORTFOLIO AT 73RD ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY

Tags:

GAITHERSBURG, MD, October 15, 2009 – MedImmune today announced that researchers will present data on several inflammatory disease programs at the annual meeting of the American College of Rheumatology, from October 17 to 21, 2009 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

“Through our research into novel disease pathways involved in autoimmune disorders, we continue to fulfill our mission of using scientific excellence to deliver life-changing medicines for patients with rheumatic diseases,” said Anthony Coyle, PhD., vice president, head of respiratory, inflammation, and autoimmune disease research. “Representing some of our most recent progress, we are pleased to share data relevant to the development of new therapies for conditions such as lupus, rheumatoid arthritis, and scleroderma.”

The schedule for MedImmune’s nine posters and two oral presentations at the meeting, starting on Sunday October 17, is as follows:



  • Relationship Between Disease Activity and Type 1 Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis


  • In Vitro and In Vivo Properties of MEDI-571, a Human Anti IL-17A Antibody in Development for the Treatment of Patients with Rheumatoid Arthritis



  • Utilising Assay Systems Relevant to IL-6 Mechanisms in Rheumatoid Arthritis to Demonstrate Efficacy of a Novel Human Anti-IL-6 Antibody, CAT6001



  • MEDI5117: A Human High Affinity Anti-IL-6 Monoclonal Antibody with Enhanced Serum Half-Life in Development for the Treatment of Inflammation and Rheumatological Diseases



  • Tissue Plasminogen Activator (tPA) Restores Normal Fibrinolysis / Coagulation Balance in Kidney and Reverses Clinical Score in Skin in a Murine Graft-Versus-Host Disease Model of Scleroderma: Proof of Concept for Therapeutic Fibrinolysis in Scleroderma



  • Neutralization of Angiopoietin 2 Reduces Disease in Murine Arthritis and Augments Efficacy of Anti-TNF Treatment



  • Critical Requirement of RAGE for Development of Lung Fibrosis in An Experimental Model of Systemic Sclerosis



  • Depletion of Inducible Co-Stimulator (ICOS) Bearing T Cells Inhibits Expansion of T Follicular Helper Cells (TFH) and Prevents Disease in a Graft Versus Host Mouse Model of Scleroderma



  • Autoimmune-Driven Skin Fibrosis: The Critical Requirement for IFNAR1 in An Experimental Model of Systemic Sclerosis



  • Human S100 Proteins Differentially Regulate Pro-Inflammatory Cytokine Release and Cell Migration



  • CAM-3001; a Novel Human Monoclonal Antibody against GM-CSFR-á, in Subjects with Rheumatoid Arthritis (RA): Results of a Phi Study


About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health.

(Oral Presentation) – Gerd-R Burmester, M.D., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1926– Bo Chen, Ph.D., Tuesday, October 20 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1331 – Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1067– Gianluca Carlesso, Ph.D., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1065–Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1053– Brian Naiman, MS., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 666 – Timothy Burwell, B.Sc., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1062– Jacques Moisan, Ph.D., Sunday, October 18 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 401–Donna Finch, Ph.D., Sunday, October 18 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 45, Abstract: 587

(Oral Presentation)–Steven Greeberg, Ph.D., Sunday, October 18 at 3:00 p.m. in Room 202 B


– Matthew Sleeman, Ph.D., Sunday, October 18 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 8

For more information, visit MedImmune’s website at www.medimmune.com.